HU229483B1 - Mutilin derivatives and their use as antibacterials - Google Patents

Mutilin derivatives and their use as antibacterials Download PDF

Info

Publication number
HU229483B1
HU229483B1 HU0202071A HUP0202071A HU229483B1 HU 229483 B1 HU229483 B1 HU 229483B1 HU 0202071 A HU0202071 A HU 0202071A HU P0202071 A HUP0202071 A HU P0202071A HU 229483 B1 HU229483 B1 HU 229483B1
Authority
HU
Hungary
Prior art keywords
aromatic
formula
compound
compounds
hydrogen
Prior art date
Application number
HU0202071A
Other languages
English (en)
Hungarian (hu)
Inventor
Gerd Ascher
Heinz Dr Berner
Johannes Hildebrandt
Original Assignee
Nabriva Therapeutics Forschungs Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabriva Therapeutics Forschungs Gmbh filed Critical Nabriva Therapeutics Forschungs Gmbh
Publication of HUP0202071A2 publication Critical patent/HUP0202071A2/hu
Publication of HUP0202071A3 publication Critical patent/HUP0202071A3/hu
Publication of HU229483B1 publication Critical patent/HU229483B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/76—Ring systems containing bridged rings containing three rings containing at least one ring with more than six ring members
    • C07C2603/80—Ring systems containing bridged rings containing three rings containing at least one ring with more than six ring members containing eight-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0202071A 1999-07-30 2000-07-28 Mutilin derivatives and their use as antibacterials HU229483B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9918037.4A GB9918037D0 (en) 1999-07-30 1999-07-30 Organic compounds
PCT/EP2000/007309 WO2001009095A1 (en) 1999-07-30 2000-07-28 Mutilin derivatives and their use as antibacterials

Publications (3)

Publication Number Publication Date
HUP0202071A2 HUP0202071A2 (en) 2002-10-28
HUP0202071A3 HUP0202071A3 (en) 2003-03-28
HU229483B1 true HU229483B1 (en) 2014-01-28

Family

ID=10858319

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202071A HU229483B1 (en) 1999-07-30 2000-07-28 Mutilin derivatives and their use as antibacterials

Country Status (34)

Country Link
US (2) US6784193B1 (enExample)
EP (2) EP1198454B1 (enExample)
JP (2) JP4711580B2 (enExample)
KR (2) KR100878074B1 (enExample)
CN (2) CN1636976A (enExample)
AR (1) AR024964A1 (enExample)
AT (2) ATE319686T1 (enExample)
AU (1) AU757799B2 (enExample)
BR (2) BRPI0017527B1 (enExample)
CA (1) CA2380980C (enExample)
CO (1) CO5180568A1 (enExample)
CZ (1) CZ2002345A3 (enExample)
DE (2) DE60026540T2 (enExample)
DK (1) DK1198454T3 (enExample)
EC (1) ECSP003591A (enExample)
ES (2) ES2259610T3 (enExample)
GB (1) GB9918037D0 (enExample)
HK (1) HK1047087B (enExample)
HU (1) HU229483B1 (enExample)
IL (2) IL147072A0 (enExample)
MX (1) MXPA02001091A (enExample)
MY (1) MY133731A (enExample)
NO (1) NO322562B1 (enExample)
NZ (1) NZ516711A (enExample)
PE (1) PE20010544A1 (enExample)
PL (1) PL205609B1 (enExample)
PT (1) PT1198454E (enExample)
RU (1) RU2276135C2 (enExample)
SI (1) SI1198454T1 (enExample)
SK (1) SK1272002A3 (enExample)
TR (1) TR200103764T2 (enExample)
TW (1) TWI281468B (enExample)
WO (1) WO2001009095A1 (enExample)
ZA (1) ZA200200695B (enExample)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020676A1 (es) 2000-09-13 2002-08-27 Biochemie Gmbh Compuestos de mutilina como antibacterianos
GB0207495D0 (en) * 2002-03-28 2002-05-08 Biochemie Gmbh Organic compounds
GB0209262D0 (en) * 2002-04-23 2002-06-05 Biochemie Gmbh Organic compounds
DE60317208T2 (de) * 2002-07-24 2008-08-07 Nabriva Therapeutics Forschungs Gmbh Pleuromutilinderivate als antimikrobielle mittel
ATE450535T1 (de) * 2003-09-03 2009-12-15 Glaxo Group Ltd Neues verfahren zur herstellung von pleuromutilinderivaten
GB0504314D0 (en) * 2005-03-02 2005-04-06 Glaxo Group Ltd Novel polymorph
EP1860943A4 (en) * 2005-03-10 2008-06-18 Smithkline Beecham Corp NOVEL PROCEDURE
GB0513058D0 (en) * 2005-06-27 2005-08-03 Sandoz Ag Organic compounds
GB0515995D0 (en) * 2005-08-03 2005-09-07 Sandoz Ag Organic compounds
WO2007037518A1 (ja) * 2005-09-29 2007-04-05 Dainippon Sumitomo Pharma Co., Ltd. ムチリン誘導体及びそれを含有する医薬組成物
EP1808431A1 (en) * 2006-01-16 2007-07-18 Nabriva Therapeutics Forschungs GmbH Mutilin derivatives and their use as pharmaceutical
US8841334B2 (en) * 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
EP2024349B1 (en) * 2006-05-31 2017-08-02 AbbVie Inc. Compounds as cannabinoid receptor ligands and uses thereof
BRPI0712720A2 (pt) * 2006-05-31 2012-11-20 Abbott Lab compostos tiazàis como ligantes do receptor canabinàide e usos dos mesmos
WO2007143507A2 (en) * 2006-06-05 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted erythromycin analogs
EP1908750A1 (en) * 2006-10-05 2008-04-09 Nabriva Therapeutics Forschungs GmbH Process for the preparation of pleuromutilins
EP1972618A1 (en) * 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin derivatives for the treatment of diseases mediated by microbes
JP2010522760A (ja) 2007-03-28 2010-07-08 アボット・ラボラトリーズ カンナビノイド受容体リガンドとしての１，３−チアゾール−２（３ｈ）−イリデン化合物
US8501794B2 (en) * 2007-04-17 2013-08-06 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7872033B2 (en) * 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2008144360A1 (en) * 2007-05-18 2008-11-27 Abbott Laboratories Novel compounds as cannabinoid receptor ligands
JP5322927B2 (ja) * 2007-05-24 2013-10-23 杏林製薬株式会社 １４位置換基に複素芳香環カルボン酸構造を有するムチリン誘導体
EP2014640A1 (en) * 2007-07-13 2009-01-14 Nabriva Therapeutics AG Pleuromutilin derivatives
EP2014645A1 (en) * 2007-07-13 2009-01-14 Nabriva Therapeutics AG Pleuromutilin derivatives and their use as antimicrobials
US9193713B2 (en) * 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
JP2011513495A (ja) 2008-03-11 2011-04-28 アボット・ラボラトリーズ カンナビノイド受容体リガンドとしての新規な化合物
EP2271625B1 (en) 2008-04-01 2012-09-12 Abbott GmbH & Co. KG Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
MX2011001370A (es) * 2008-08-05 2011-03-15 Abbott Lab Compuestos utiles como inhibidores de cinasas de proteina.
CN102123993A (zh) * 2008-08-15 2011-07-13 雅培制药有限公司 作为大麻素受体配体的亚胺衍生物
US8846730B2 (en) 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
CA2737199A1 (en) 2008-09-16 2010-03-25 Abbott Laboratories Novel compounds as cannabinoid receptor ligands
UY32180A (es) * 2008-10-17 2010-05-31 Abbott Lab Antagonistas del receptor transitorio potencial de vanilloides 1 (trpv1)
US8609692B2 (en) * 2008-10-17 2013-12-17 Abbvie Inc. TRPV1 antagonists
US20100184987A1 (en) * 2008-11-13 2010-07-22 Teva Pharmaceutical Industries Ltd. Preparation of Retapamulin via its Pleuromutilin-thiol precursor
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
NZ614305A (en) 2008-12-05 2015-03-27 Abbvie Inc Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
PA8854001A1 (es) 2008-12-16 2010-07-27 Abbott Lab Compuestos novedosos como ligandos de receptores de canabinoides
NZ616828A (en) * 2009-01-19 2015-03-27 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
RU2538965C2 (ru) * 2009-01-19 2015-01-10 Эббви Инк. Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
TWI519530B (zh) * 2009-02-20 2016-02-01 艾伯維德國有限及兩合公司 羰醯胺化合物及其作為鈣蛋白酶（ｃａｌｐａｉｎ）抑制劑之用途
US8236822B2 (en) * 2009-03-27 2012-08-07 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2010111573A1 (en) * 2009-03-27 2010-09-30 Abbott Laboratories Compounds as cannabinoid receptor ligands
CA2756178A1 (en) 2009-03-27 2010-09-30 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8507493B2 (en) * 2009-04-20 2013-08-13 Abbvie Inc. Amide and amidine derivatives and uses thereof
US8236798B2 (en) 2009-05-07 2012-08-07 Abbott Gmbh & Co. Kg Carboxamide compounds and their use as calpain inhibitors
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
ES2546294T7 (es) 2009-05-26 2024-06-06 Abbvie Ireland Unlimited Co Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8962639B2 (en) * 2009-05-29 2015-02-24 Abbvie Inc. Potassium channel modulators
WO2011053740A1 (en) 2009-10-28 2011-05-05 Belkin International, Inc. Portable multi-media communication device protective carrier and method of manufacture therefor
CN102666495A (zh) 2009-11-25 2012-09-12 雅培制药有限公司 钾通道调节剂
TW201130855A (en) * 2009-12-16 2011-09-16 Abbott Lab Prodrug compounds useful as cannabinoid ligands
AU2011229862B2 (en) 2010-03-25 2014-07-24 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
US8586596B2 (en) 2010-06-15 2013-11-19 Abbvie Inc. Compounds as cannabinoid receptor ligands
JP2013538800A (ja) 2010-08-10 2013-10-17 アッヴィ・インコーポレイテッド 新規ｔｒｐｖ３モジュレーター
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9266855B2 (en) 2010-09-27 2016-02-23 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
KR20180059560A (ko) 2010-10-29 2018-06-04 애브비 인코포레이티드 아폽토시스―유도제를 포함하는 고체 분산체
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
WO2012059431A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
WO2012059432A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
US20120122924A1 (en) 2010-11-15 2012-05-17 Abbott Laboratories Nampt inhibitors
SG10202010119TA (en) 2010-11-15 2020-11-27 Abbvie Inc NAMPT And Rock Inhibitors
WO2012067824A1 (en) 2010-11-16 2012-05-24 Abbott Laboratories Potassium channel modulators
US8609669B2 (en) 2010-11-16 2013-12-17 Abbvie Inc. Potassium channel modulators
WO2012071336A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Salts and crystalline forms of an apoptosis-inducing agent
RU2593231C2 (ru) 2010-11-23 2016-08-10 ЭббВи Айэленд Анлимитед Компани Способы лечения с использованием селективных ингибиторов bcl-2
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US8802693B1 (en) 2011-03-09 2014-08-12 Abbvie Inc. Azaadamantane derivatives and methods of use
WO2012129491A1 (en) 2011-03-24 2012-09-27 Abbott Laboratories Trpv3 modulators
WO2012134943A1 (en) 2011-03-25 2012-10-04 Abbott Laboratories Trpv1 antagonists
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2012158399A1 (en) 2011-05-13 2012-11-22 Abbott Laboratories Condensed 2 - carbamoylpyridazinones as potassium channel modulators
MX2014001457A (es) 2011-08-05 2014-08-21 Abbvie Deutschland Derivados de aminocromano, de aminotiocromano y de amino-1,2,3,4-tetrahidroquinolina composiciones farmaceuticas que los contienen, y su uso en terapia.
TWI571466B (zh) 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
TWI561521B (en) 2011-10-14 2016-12-11 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN104254522A (zh) 2011-10-24 2014-12-31 艾伯维公司 作为trpv3调节剂的甲醇衍生物
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
WO2013072520A1 (en) 2011-11-18 2013-05-23 AbbVie Deutschland GmbH & Co. KG N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8859584B2 (en) 2011-12-19 2014-10-14 Abbvie, Inc. TRPV1 antagonists
US8969325B2 (en) 2011-12-19 2015-03-03 Abbvie Inc. TRPV1 antagonists
CN103204787B (zh) * 2012-01-17 2014-10-01 北京艾百诺科技有限公司 含有取代方酸的乙酸妙林酯及其应用
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013149376A1 (en) 2012-04-02 2013-10-10 Abbott Laboratories Chemokine receptor antagonists
WO2013155695A1 (en) 2012-04-20 2013-10-24 Abbott Laboratories Isoindolone derivatives
EP2852585A1 (en) 2012-05-11 2015-04-01 AbbVie Inc. Nampt inhibitors
MX2014013758A (es) 2012-05-11 2015-02-05 Abbvie Inc Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
US20130303509A1 (en) 2012-05-11 2013-11-14 Abbvie Inc. Nampt inhibitors
AR091022A1 (es) 2012-05-11 2014-12-30 Abbvie Inc Inhibidores del nampt
US20130317055A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Neuronal nicotinic agonist and methods of use
US20130317054A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Neuronal nicotinic agonist and methods of use
HK1208681A1 (en) 2012-06-12 2016-03-11 Abbvie Inc. Pyridinone and pyridazinone derivatives
US8796328B2 (en) 2012-06-20 2014-08-05 Abbvie Inc. TRPV1 antagonists
CN103626693B (zh) * 2012-08-28 2016-09-14 中国科学院上海药物研究所 一类截短侧耳素衍生物、其药物组合物及其合成方法与用途
US20140080813A1 (en) 2012-09-14 2014-03-20 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives
BR112015005743A2 (pt) 2012-09-14 2017-07-04 Abbvie Deutschland derivados tricíclicos de quinoxalina e quinolina
TW201444820A (zh) 2013-03-13 2014-12-01 Abbvie Inc 吡啶ｃｄｋ９激酶抑制劑
JP2016512559A (ja) 2013-03-13 2016-04-28 アッヴィ・インコーポレイテッド Ｃｄｋ９キナーゼ阻害薬
CN105189512A (zh) 2013-03-14 2015-12-23 艾伯维公司 吡咯并嘧啶cdk9激酶抑制剂
MX2015012899A (es) 2013-03-14 2016-06-02 Abbvie Inc Pirrolo [2,3-b] piridina como inhibidores de quinasa cdk9.
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN105339366A (zh) 2013-03-14 2016-02-17 艾伯维德国有限责任两合公司 带有取代的氧杂环丁烷的2-吲哚酮衍生物及其治疗血管加压素相关疾病的用途
MX2015012008A (es) 2013-03-14 2016-04-15 Abbvie Deutschland Compuestos inhibidores novedosos de fosfodiesterasa tipo 10a.
TW201446763A (zh) 2013-03-14 2014-12-16 Abbvie Inc 吡咯并［２，３－ｂ］吡啶ｃｄｋ９激酶抑制劑
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
JP2016533375A (ja) 2013-10-17 2016-10-27 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー アミノテトラリン誘導体およびアミノインダン誘導体、これらを含有する医薬組成物、および治療におけるこれらの使用
CA2924689A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2015091931A1 (en) 2013-12-20 2015-06-25 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseases
US9328112B2 (en) 2014-02-06 2016-05-03 Abbvie Inc. Tetracyclic CDK9 kinase inhibitors
US9527856B2 (en) 2014-05-15 2016-12-27 AbbVie Deutschland GmbH & Co. KG Oxindole compounds carrying a CO-bound spiro substituent and use thereof for treating vasopressin-related diseases
WO2016034703A1 (en) 2014-09-05 2016-03-10 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2016160938A1 (en) 2015-04-02 2016-10-06 Abbvie Inc. N-(1,3-thiazol-2-yl)pyrimidine-5-carboxamides as trpv3 modulators
US20180339996A1 (en) 2015-11-25 2018-11-29 AbbVie Deutschland GmbH & Co. KG Hexahydropyrazinobenz- or -pyrido-oxazepines carrying an oxygen-containing substituent and use thereof in the treatment of 5-ht2c-dependent disorders
ES2954148T3 (es) 2016-05-07 2023-11-20 Fochon Pharmaceuticals Ltd Ciertos inhibidores de proteína cinasa
CN106565564A (zh) * 2016-09-30 2017-04-19 华南农业大学 一种具有2‑氨基苯巯醇侧链的截短侧耳素衍生物及其制备方法和用途
WO2018058534A1 (zh) * 2016-09-30 2018-04-05 华南农业大学 一种具有2-氨基苯巯醇侧链的截短侧耳素衍生物及其制备方法和用途
US11168078B2 (en) 2016-11-28 2021-11-09 Shanghai Fochon Pharmaceutical Co., Ltd. Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2,3-dioxygenase
TWI762573B (zh) 2017-02-10 2022-05-01 奧地利商納畢瓦治療有限責任公司 截短側耳素之純化
US20200039930A1 (en) 2017-03-21 2020-02-06 AbbVie Deutschland GmbH & Co. KG Proline amide compounds and their azetidine analogues carrying a specifically substituted benzyl radical
SI3612531T1 (sl) 2017-04-18 2022-11-30 Shanghai Fochon Pharmaceutical Co., Ltd. Sredstva, ki sprožajo apoptozo
CN107417586A (zh) * 2017-06-21 2017-12-01 华南农业大学 一种截短侧耳素类抗生素及其制备方法和应用
CN109384698B (zh) * 2017-08-04 2022-07-08 保定加合精细化工有限公司 一种双萜烯类畜禽用抗生素的制备方法
BR112020018444A2 (pt) 2018-03-14 2020-12-29 Fochon Pharmaceuticals, Ltd. Compostos de (2-azabiciclo[3,1,0]hexan-2-il)pirazolo[1,5-a]pirimidina substituída e imidazo[1,2-b]piridazina como inibidores de trk cinases
JP2021517137A (ja) 2018-03-23 2021-07-15 フォチョン・ファーマシューティカルズ・リミテッドＦｏｃｈｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｌｔｄ． Ｒｏｃｋ阻害剤としての重水素化合物
CN115197169B (zh) * 2018-11-02 2023-07-11 华南农业大学 一种以2-氨基苯巯醇为连接基团截短侧耳素衍生物制备方法和用途
CN110372615B (zh) * 2019-07-08 2023-02-03 华南农业大学 一种具有2-氨基苯硫醇和1,2,3-三氮唑侧链的截短侧耳素衍生物及制备与应用
CN111170911A (zh) * 2019-09-29 2020-05-19 安帝康（无锡）生物科技有限公司 用于治疗细菌感染性疾病的截短侧耳素类化合物
CN110818648B (zh) * 2019-12-05 2021-03-16 华南农业大学 一种具有三氮唑侧链的截短侧耳素衍生物及其制备方法和应用
CN113666883B (zh) * 2021-07-23 2023-06-16 华南理工大学 一种合成4-乙烯基异噁唑衍生物的方法
CN114940671A (zh) * 2022-05-10 2022-08-26 华南农业大学 一种具有4-氨基苯硫醇侧链的截短侧耳素衍生物及其制备方法和应用
CN115850137B (zh) * 2022-11-12 2024-04-12 中国农业科学院兰州畜牧与兽药研究所 一种截短侧耳素衍生化合物及其制备方法与应用
CN117945965A (zh) * 2024-01-22 2024-04-30 新疆上昵生物科技有限公司 泰妙菌素的制备方法
CN120607472B (zh) * 2025-08-06 2025-10-17 重庆市畜牧科学院 一种截短侧耳素衍生物及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107164A (en) 1971-10-05 1978-08-15 Sandoz Ltd. Certain pleuromulilin ester derivatives
BE789629A (fr) * 1971-10-05 1973-04-03 Sandoz Sa Nouveaux derives de la pleuromutiline, leur preparation et leurapplication en therapeutique
JPS54160358A (en) * 1978-06-06 1979-12-19 Sandoz Ag Improvement for organic compound
JPS5594359A (en) * 1979-01-12 1980-07-17 Sandoz Ag Novel pleuromutilin derivatives*their manufacture and use
EP0013768B1 (en) * 1979-01-12 1984-02-01 Sandoz Ag New pleuromutilin derivatives, their production and pharmaceutical compositions containing them
DE3405632A1 (de) * 1984-02-17 1985-08-22 Sandoz-Patent-GmbH, 7850 Lörrach Neue pleuromutilinderivate, verfahren zu ihrer herstellung und ihre verwendung
EP0153277B1 (de) * 1984-02-17 1987-08-26 Sandoz Ag Neue Pleuromutilinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung
HU208115B (en) 1989-10-03 1993-08-30 Biochemie Gmbh New process for producting pleuromutilin derivatives
AT397654B (de) * 1992-05-04 1994-06-27 Biochemie Gmbh Neue pleuromutilinderivate, ihre verwendung und verfahren zu ihrer herstellung
GB9614017D0 (en) * 1996-07-04 1996-09-04 Biochemie Gmbh Organic compounds
UY25225A1 (es) * 1997-10-29 2000-12-29 Smithkline Beecham Plc Derivados de pleuromutilina utiles como agentes antimicrobianos
WO2000027790A1 (en) * 1998-11-11 2000-05-18 Smithkline Beecham P.L.C. Mutilin compounds
PE20020676A1 (es) * 2000-09-13 2002-08-27 Biochemie Gmbh Compuestos de mutilina como antibacterianos

Also Published As

Publication number Publication date
ES2259610T3 (es) 2006-10-16
PT1198454E (pt) 2006-07-31
HUP0202071A3 (en) 2003-03-28
CA2380980A1 (en) 2001-02-08
PL205609B1 (pl) 2010-05-31
DE60026540T2 (de) 2007-01-18
ATE490240T1 (de) 2010-12-15
SI1198454T1 (sl) 2006-08-31
IL147072A0 (en) 2002-08-14
NO20020383L (no) 2002-01-24
US6784193B1 (en) 2004-08-31
MY133731A (en) 2007-11-30
TWI281468B (en) 2007-05-21
KR100878075B1 (ko) 2009-01-13
AU6832600A (en) 2001-02-19
DK1198454T3 (da) 2006-06-12
AR024964A1 (es) 2002-10-30
KR20020029908A (ko) 2002-04-20
US7534814B2 (en) 2009-05-19
HK1047087A1 (en) 2003-02-07
CN1182116C (zh) 2004-12-29
ATE319686T1 (de) 2006-03-15
CO5180568A1 (es) 2002-07-30
EP1198454B1 (en) 2006-03-08
MXPA02001091A (es) 2002-10-31
WO2001009095A1 (en) 2001-02-08
KR100878074B1 (ko) 2009-01-13
CA2380980C (en) 2009-04-14
IL147072A (en) 2007-09-20
EP1666466A2 (en) 2006-06-07
BRPI0017527B8 (enExample) 2021-05-25
BR0012880A (pt) 2002-04-09
PE20010544A1 (es) 2001-05-15
KR20070087245A (ko) 2007-08-27
CN1364158A (zh) 2002-08-14
TR200103764T2 (tr) 2002-06-21
JP4711580B2 (ja) 2011-06-29
DE60026540D1 (de) 2006-05-04
GB9918037D0 (en) 1999-09-29
DE60045321D1 (de) 2011-01-13
RU2276135C2 (ru) 2006-05-10
EP1666466A3 (en) 2007-09-26
NO20020383D0 (no) 2002-01-24
JP5485838B2 (ja) 2014-05-07
EP1198454A1 (en) 2002-04-24
HK1090636A1 (en) 2006-12-29
US20040235910A1 (en) 2004-11-25
HK1047087B (en) 2006-12-22
ZA200200695B (en) 2003-05-28
ECSP003591A (es) 2002-02-25
SK1272002A3 (en) 2002-07-02
PL352940A1 (en) 2003-09-22
JP2003506354A (ja) 2003-02-18
NO322562B1 (no) 2006-10-23
CZ2002345A3 (cs) 2002-05-15
JP2011016834A (ja) 2011-01-27
CN1636976A (zh) 2005-07-13
NZ516711A (en) 2003-07-25
ES2357443T3 (es) 2011-04-26
BRPI0017527B1 (pt) 2017-08-29
AU757799B2 (en) 2003-03-06
HUP0202071A2 (en) 2002-10-28
EP1666466B1 (en) 2010-12-01

Similar Documents

Publication Publication Date Title
RU2276135C2 (ru) Производные мутилинов и их применение в качестве антибактериальных средств
US7626032B2 (en) Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
HU194819B (en) Process for producing pleuromutilin derivatives and pharmaceutical compositions containing them
JP5134181B2 (ja) 抗菌性ムチリン
TWI414511B (zh) 有機化合物
US20020045574A1 (en) Glycopeptide antibacterial compounds and methods of using same
EP4219437B1 (en) Bakuchiol derivative, pharmaceutically acceptable salt thereof, preparation method therefor and application thereof
EP0393538A2 (en) Thiazetoquinoline-3-Carboxylic acid derivative, method for preparation thereof, and a pharmaceutical composition comprising the same
HK1090636B (en) Mutilin derivatives and their use as antimicrobials
HK40089915A (en) Bakuchiol derivative, pharmaceutically acceptable salt thereof, preparation method therefor and application thereof
HK40089915B (en) Bakuchiol derivative, pharmaceutically acceptable salt thereof, preparation method therefor and application thereof

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: NABRIVA THERAPEUTICS FORSCHUNGS GMBH, AT

Free format text: FORMER OWNER(S): BIOCHEMIE GESELLSCHAFT MBH., AT; SANDOZ AG, CH